Yhdysvallat - englanti - NLM (National Library of Medicine)

lake erie medical dba quality care products llc - armodafinil (unii: v63xwa605i) (armodafinil - unii:v63xwa605i) - armodafinil 150 mg - nuvigil is indicated to improve wakefulness in patients with excessive sleepiness associated with obstructive sleep apnea, narcolepsy and shift work disorder. in osa, nuvigil is indicated as an adjunct to standard treatment(s) for the underlying obstruction. if continuous positive airway pressure (cpap) is the treatment of choice for a patient, a maximal effort to treat with cpap for an adequate period of time should be made prior to initiating nuvigil. if nuvigil is used adjunctively with cpap, the encouragement of and periodic assessment of cpap compliance is necessary. in all cases, careful attention to the diagnosis and treatment of the underlying sleep disorder(s) is of utmost importance. prescribers should be aware that some patients may have more than one sleep disorder contributing to their excessive sleepiness. the effectiveness of nuvigil in long-term use (greater than 12 weeks) has not been systematically evaluated in placebo-controlled trials. the physician who elects to prescribe nuvigil for an e

Yhdysvallat - englanti - NLM (National Library of Medicine)

bausch & lomb incorporated - ipratropium bromide (unii: j697uz2a9j) (ipratropium - unii:gr88g0i6ul) - ipratropium bromide anhydrous 21 ug - ipratropium bromide nasal solution 0.03% (nasal spray) is indicated for the symptomatic relief of rhinorrhea associated with allergic and nonallergic perennial rhinitis in adults and children age 6 years and older. ipratropium bromide nasal solution 0.03% (nasal spray) does not relieve nasal congestion, sneezing, or postnasal drip associated with allergic or nonallergic perennial rhinitis. ipratropium bromide nasal solution 0.03% (nasal spray) is contraindicated in patients with a history of hypersensitivity to atropine or its derivatives, or to any of the other ingredients. ipratropium bromide nasal solution 0.03% (nasal spray) 21 mcg/spray rx only read complete instructions carefully before using.   in order to ensure proper dosing, do not attempt to change the size of the spray opening. ipratropium bromide nasal solution 0.03% (nasal spray) is indicated for the symptomatic relief of rhinorrhea (runny nose) associated with allergic and nonallergic perennial rhinitis in adults and children age 6 years and older. ipratropium bromide nasal solution 0.03% (nasal spray) does not relieve nasal congestion, sneezing, or postnasal drip associated with allergic or nonallergic perennial rhinitis. read complete instructions carefully and use only as directed. to use: 1. remove the plastic dust cap and the safety clip from the nasal spray pump (figure 1). the safety clip prevents the accidental discharge of the spray in your pocket or purse. 2. the nasal spray pump must be primed before ipratropium bromide nasal solution 0.03% (nasal spray) is used for the first time. to prime the pump, hold the bottle with your thumb at the base and your index and middle fingers on the white shoulder area. make sure the bottle points upright and away from your eyes. press your thumb firmly and quickly against the bottle seven (7) times (figure 2). the pump is now primed and can be used. your pump should not have to be reprimed unless you have not used the medication for more than 24 hours; repriming the pump will only require two sprays. if you have not used your nasal spray for more than seven (7) days, repriming the pump will require seven sprays. 3. before using ipratropium bromide nasal solution 0.03% (nasal spray), blow your nose gently to clear your nostrils if necessary. 4. close one nostril by gently placing your finger against the side of your nose, tilt your head slightly forward and, keeping the bottle upright, insert the nasal tip into the other nostril (figure 3). point the tip toward the back and outer side of the nose. 5. press firmly and quickly upwards with the thumb at the base while holding the white shoulder portion of the pump between your index and middle fingers. following each spray, sniff deeply and breathe out through your mouth. 6. after spraying the nostril and removing the unit, tilt your head backwards for a few seconds to let the spray spread over the back of the nose. 7. repeat steps 4 through 6 in the same nostril. 8. repeat steps 4 through 7 in the other nostril (i.e., two sprays per nostril). 9. replace the plastic dust cap and safety clip. 10. at some time before the medication is completely used up, you should consult your physician or pharmacist to determine whether a refill is needed. you should not take extra doses or stop using ipratropium bromide nasal solution 0.03% (nasal spray) without consulting your physician. to clean: if the nasal tip becomes clogged, remove the plastic dust cap and safety clip. hold the nasal tip under running, warm tap water (figure 4) for about a minute. dry the nasal tip, reprime the nasal spray pump (step 2 above), and replace the plastic dust cap and safety clip.   caution: ipratropium bromide nasal solution 0.03% (nasal spray) is intended to relieve your rhinorrhea (runny nose) with regular use. it is therefore important that you use ipratropium bromide nasal solution 0.03% (nasal spray) as prescribed by your physician. for most patients, some improvement in runny nose is usually apparent during the first full day of treatment with ipratropium bromide nasal solution 0.03% (nasal spray). some patients may require up to two weeks of treatment to obtain maximum benefit. do not spray ipratropium bromide nasal solution 0.03% (nasal spray) in your eyes. should this occur, immediately flush your eye with cool tap water for several minutes. if you accidentally spray ipratropium bromide nasal solution 0.03% (nasal spray) in your eyes, you may experience a temporary blurring of vision, visual halos or colored images in association with red eyes from conjunctival and corneal congestion, development or worsening of narrow-angle glaucoma, pupil dilation, or acute eye pain/discomfort, and increased sensitivity to light, which may last a few hours. should acute eye pain or blurred vision occur, contact your doctor. should you experience excessive nasal dryness or episodes of nasal bleeding, contact your doctor. if you have glaucoma or difficulty urinating due to an enlargement of the prostate, be sure to tell your physician prior to using ipratropium bromide nasal solution 0.03% (nasal spray). if you are pregnant or you are breast feeding your baby, be sure to tell your physician prior to using ipratropium bromide nasal solution 0.03% (nasal spray). storage: store at 68° to 77°f (20° to 25°c); excursions are permitted to 59° to 86°f (15° to 30°c). avoid freezing. keep out of reach of children. to report suspected adverse reactions, contact bausch & lomb incorporated at 1-800-321-4576 or fda at 1-800-fda-1088 or www.fda.gov/medwatch. distributed by: bausch + lomb, a division of bausch health us, llc bridgewater, nj 08807 usa manufactured by: bausch health companies inc. laval, quebec h7l 4a8, canada © 2019 bausch & lomb incorporated or its affiliates revised: may 2019 9682401 (folded)

Yhdysvallat - englanti - NLM (National Library of Medicine)

oceanside pharmaceuticals - butalbital (unii: khs0az4jvk) (butalbital - unii:khs0az4jvk), acetaminophen (unii: 362o9itl9d) (acetaminophen - unii:362o9itl9d) - butalbital 50 mg - butalbital and acetaminophen tablets are indicated for the relief of the symptom complex of tension (or muscle contraction) headache. evidence supporting the efficacy and safety of this combination product in the treatment of multiple recurrent headaches is unavailable. caution in this regard is required because butalbital is habit-forming and potentially abusable. this product is contraindicated under the following conditions: abuse and dependence: butalbital: barbiturates may be habit-forming: tolerance, psychological dependence, and physical dependence may occur especially following prolonged use of high doses of barbiturates. the average daily dose for the barbiturate addict is usually about 1500 mg. as tolerance to barbiturates develops, the amount needed to maintain the same level of intoxication increases; tolerance to a fatal dosage, however, does not increase more than two-fold. as this occurs, the margin between an intoxication dosage and fatal dosage becomes smaller. the lethal dose of a barbiturat

Yhdysvallat - englanti - NLM (National Library of Medicine)

bausch & lomb incorporated - acetylcholine chloride (unii: af73293c2r) (acetylcholine - unii:n9yns0m02x) - acetylcholine chloride 20 mg in 2 ml - to obtain miosis of the iris in seconds after delivery of the lens in cataract surgery, in penetrating keratoplasty, iridectomy, and other anterior segment surgery where rapid miosis may be required. miochol-e is contraindicated in persons with a known hypersensitivity to any component of this product.

Yhdysvallat - englanti - NLM (National Library of Medicine)

oceanside pharmaceuticals - diltiazem hydrochloride (unii: olh94387te) (diltiazem - unii:ee92bbp03h) - diltiazem hydrochloride 30 mg - diltiazem hydrochloride tablets are indicated for the management of chronic stable angina and angina due to coronary artery spasm. diltiazem hydrochloride tablets are contraindicated in:

Yhdysvallat - englanti - NLM (National Library of Medicine)

bausch health us llc - diltiazem hydrochloride (unii: olh94387te) (diltiazem - unii:ee92bbp03h) - diltiazem hydrochloride 120 mg - cardizem cd is indicated for the treatment of hypertension. it may be used alone or in combination with other antihypertensive medications. cardizem cd is indicated for the management of chronic stable angina and angina due to coronary artery spasm. cardizem cd is contraindicated in (1) patients with sick sinus syndrome except in the presence of a functioning ventricular pacemaker, (2) patients with second- or third-degree av block except in the presence of a functioning ventricular pacemaker, (3) patients with hypotension (less than 90 mm hg systolic), (4) patients who have demonstrated hypersensitivity to the drug, and (5) patients with acute myocardial infarction and pulmonary congestion documented by x-ray on admission.

Yhdysvallat - englanti - NLM (National Library of Medicine)

preferred pharmaceuticals inc. - diclofenac sodium (unii: qtg126297q) (diclofenac - unii:144o8ql0l1) - diclofenac sodium 100 mg - carefully consider the potential benefits and risks of diclofenac sodium extended-release tablets and other treatment options before deciding to use diclofenac sodium extended-release tablets. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings; gastrointestinal bleeding, ulceration, and perforation ). diclofenac sodium extended-release tablets are indicated: diclofenac sodium extended-release tablets are contraindicated in the following patients:

Yhdysvallat - englanti - NLM (National Library of Medicine)

oceanside pharmaceuticals - diclofenac sodium (unii: qtg126297q) (diclofenac - unii:144o8ql0l1) - diclofenac sodium 100 mg - carefully consider the potential benefits and risks of diclofenac sodium extended-release tablets and other treatment options before deciding to use diclofenac sodium extended-release tablets. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings; gastrointestinal bleeding, ulceration, and perforation ). diclofenac sodium extended-release tablets are indicated: diclofenac sodium extended-release tablets are contraindicated in the following patients:

Yhdysvallat - englanti - NLM (National Library of Medicine)

bausch health us, llc - butalbital (unii: khs0az4jvk) (butalbital - unii:khs0az4jvk), acetaminophen (unii: 362o9itl9d) (acetaminophen - unii:362o9itl9d) - butalbital 50 mg - bupap tablets are indicated for the relief of the symptom complex of tension (or muscle contraction) headache. evidence supporting the efficacy and safety of this combination product in the treatment of multiple recurrent headaches is unavailable. caution in this regard is required because butalbital is habit-forming and potentially abusable. this product is contraindicated under the following conditions: abuse and dependence: butalbital: barbiturates may be habit-forming: tolerance, psychological dependence, and physical dependence may occur especially following prolonged use of high doses of barbiturates. the average daily dose for the barbiturate addict is usually about 1500 mg. as tolerance to barbiturates develops, the amount needed to maintain the same level of intoxication increases; tolerance to a fatal dosage, however, does not increase more than two-fold. as this occurs, the margin between an intoxication dosage and fatal dosage becomes smaller. the lethal dose of a barbiturate is far less if alcoho

Yhdysvallat - englanti - NLM (National Library of Medicine)

bausch health us, llc - amobarbital sodium (unii: g0313knc7d) (amobarbital - unii:gwh6ij239e) - amobarbital sodium 0.5 g in 5 ml - amobarbital sodium is contraindicated in patients who are hypersensitive to barbiturates, in patients with a history of manifest or latent porphyria, and in patients with marked impairment of liver function or respiratory disease in which dyspnea or obstruction is evident. amobarbital sodium is a schedule ii drug. barbiturates may be habit-forming. tolerance, psychological dependence, and physical dependence may occur, especially following prolonged use of high doses of barbiturates. daily administration in excess of 400 mg of pentobarbital or secobarbital for approximately 90 days is likely to produce some degree of physical dependence. a dosage of 600 to 800 mg for at least 35 days is sufficient to produce withdrawal seizures. the average daily dose for the barbiturate addict is usually about 1.5 g. as tolerance to barbiturates develops, the amount needed to maintain the same level of intoxication increases; tolerance to a fatal dosage, however, does not increase more than twofold. as this occurs, the margi